Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · October 19, 2017

Commercialization of Generic Angiotensin II Receptor Blockers Associated With an Increase in Adverse Events

Circulation: Cardiovascular Quality and Outcomes

 

Additional Info

Disclosure statements are available on the authors' profiles:

Circulation: Cardiovascular Quality and Outcomes
Impact of the Commercialization of Three Generic Angiotensin II Receptor Blockers on Adverse Events in Quebec, Canada: A Population-Based Time Series Analysis
Circ Cardiovasc Qual Outcomes 2017 Oct 01;10(10)e003891, J Leclerc, C Blais, L Rochette, D Hamel, L Guénette, P Poirier

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading